Achieving High Non-Viral Transfection Performance for Cell Therapy Processing

Cell therapies often involve introduction of genetically transformed cells into a patient. Recently there has been renewed interest in non-viral gene modification for this application as an alternative to lentiviral vectors. Non-viral electroporation utilizing CRISPR-Cas9 is continuing to show improved performance and safety benefits in the area of cell-based immunotherapy. Furthermore, because electroporation is easy and rapid, it can transfect a large number of cells in a short time once optimum electroporation conditions are determined.

Watch this webinar to:

• Understand how process flexibility and ability to optimize electroporation protocols can assist through the process development phase of a cell therapy program
• Discuss the typical numbers of cells required for cell therapy process development and manufacturing applications
  
• Explore the safety, performance and regulatory advantages of mechanical, non-viral transfection for cell therapy